Therefore, this retrospective analysis aimed to evaluate baseline 18F-flotufolastat PET parameters (e.g., total tumor volume (TTV), whole-body SUVmax) as potential prognostic parameters for prostate-specific antigen (PSA) response, PSA-progression-free survival (PSA-PFS) and OS in a large cohort of mCRPC patients receiving 177Lu-labeled PSMA-RLT. This evidence concerns the gene FOLH1 and neoplasm.